A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer

By  

Medical Oncology, Vol. 24, Iss. 2, 2007-06 ,pp. : 137-146

Humana Press, Inc

Access to resources Recommend Favorite

CPT-11 for bile-duct and gallbladder carcinoma: A phase II north central cancer treatment group (NCCTG) study

By Alberts Steven   Fishkin Paul   Burgart Lawrence   Cera Peter   Mahoney Michelle   Morton Roscoe   Johnson Patricia   Nair Suresh   Goldberg Richard  

International Journal of Gastrointestinal Cancer, Vol. 32, Iss. 2-3, 2002-12 ,pp. : 107-114

Humana Press, Inc

Access to resources Recommend Favorite

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)

By Van Cutsem E.   Cunningham D.   Ten Bokkel Huinink W.W.   Punt C.J.A.   Alexopoulos C.G.   Dirix L.   Symann M.   Blijham G.H.   Cholet P.   Fillet G.   Van Groeningen C.   Vannetzel J.M.   Levi F.   Panagos G.   Unger C.   Wils J.   Cote C.   Blanc C.   Herait P.   Bleiberg H.  

European Journal of Cancer, Vol. 35, Iss. 1, 1999-01 ,pp. : 54-59

Elsevier

Access to resources Recommend Favorite

Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer

By Cassinello J.   López-Alvarez P.   Martínez-Guisado A.   Valladares M.   Huidobro G.   López R.   Bohn U.   Sevilla I.   Ballesteros P.   Jorge M.   Pérez-Carrión R.   Fernández J.   Dorta J.  

Medical Oncology, Vol. 20, Iss. 1, 2003-03 ,pp. : 37-43

Humana Press, Inc

Access to resources Recommend Favorite

Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer

By Benavides M.   García-Alfonso P.   Cobo M.   Muñoz-Martín A.   Gil-Calle S.   Carabantes F.   Villar E.   Graupera J.   Balcells M.   Pérez-Manga G.  

Medical Oncology, Vol. 21, Iss. 3, 2004-09 ,pp. : 255-262

Humana Press, Inc

Access to resources Recommend Favorite